| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2565062 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2012 | 8 Pages |
The endocannabinoids are lipid signaling molecules that bind to cannabinoid CB1 and CB2 receptors and other metabotropic and ionotropic receptors. Anandamide and 2-arachidonoyl glycerol, the two best-characterized examples, are released on demand in a stimulus-dependent manner by cleavage of membrane phospholipid precursors. Together with their receptors and metabolic enzymes, the endocannabinoids play a key role in modulating neurotransmission and synaptic plasticity in the basal ganglia and other brain areas involved in the control of motor functions and motivational aspects of behavior.This mini-review provides an update on the contribution of the endocannabinoid system to the regulation of psychomotor behaviors and its possible involvement in the pathophysiology of Parkinson's disease and schizophrenia.
► Cannabinoids have anti-dyskinetic and neuroprotective effects in Parkinson's disease. ► Endocannabinoid transmission is disturbed in animal models of schizophrenia. ► Disturbances of endocannabinoid transmission may vary in schizophrenia subtypes.
